<DOC>
	<DOCNO>NCT01441115</DOCNO>
	<brief_summary>Background : - ECI301 drug may help make cancer cell visible immune system radiation . The drug may also help immune system destroy cancer sit receive radiation therapy . Researchers want study ECI301 people advance cancer cancer spread body ( metastatic ) . Objectives : - To test ECI301 radiation therapy advance metastatic cancer . Eligibility : - People least 18 year age either metastatic advance cancer may benefit radiation therapy . Design : - Participants screen medical history physical exam . They also blood urine test , image study . - All participant radiation therapy 5 day week 2 week . - They different dos ECI301 test safety effectiveness . ECI301 give vein second week radiation therapy . Frequent blood test image study monitor treatment . - After participant ECI301 , tumor sample may take site radiation another site radiation . - Followup visit include blood test image study ... .</brief_summary>
	<brief_title>ECI301 Radiation Advanced Metastatic Cancer</brief_title>
	<detailed_description>Background : - Patients metastatic locally advanced cancer frequently require palliative radiotherapy relieve symptom ; however , progression disease frequent patient extend survival - Radiation result tumor cell death result increase dendritic cell activation traffic - ECI301 derivative Macrophage Inflammatory Protein-1 ? , 70 amino acid chemokine ligand CCR1 CCR5 , chemokine receptor immature dendritic cell . - ECI301 show enhance effect radiotherapy animal model . Objectives : - The primary objective determine maximum tolerate dose ( MTD ) ECI301 deliver combination 30 Gy external beam radiation patient metastatic locally advanced cancer . - The secondary objective : - To describe safety tolerability ECI301 deliver combination 30 Gy external beam radiation patient metastatic locally advanced cancer - To evaluate humoral cellular immune response : - Measurement circulate precursor dendritic cell completion ECI301 - Measurement circulate MIP- ? completion ECI301 - Assessment T-lymphocyte quantitative qualitative change flow cytometry assay IFN ? production - To define pharmacologic parameter follow intravenous dose ECI301 - To determine neutralize anti-EC301 antibody occur treatment - To describe response radiate site distant sit radiation combination ECI301 Eligibility : - Age &gt; 18 year . - ECOG performance status &lt; 2 . - Life expectancy great 3 month - Histologically confirm metastatic locally advanced cancer radiotherapeutic management would appropriate - No recent history myocardial infarction unstable angina Design : - This Phase I trial determine maximum tolerate dose ECI301 combination external beam radiation therapy patient locally advance metastatic solid tumor . - Patients treat radiation therapy standard manner ECI301 give daily radiation . The dose ECI301 escalate course trial determine MTD daily ECI301 combination radiotherapy . - We anticipate accrual trial 30 patient take approximately 2 year .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>INCLUSION CRITERIA : 2.1.1.1 Age great equal to18 year . 2.1.1.2 ECOG performance status less equal 2 . 2.1.1.3 Life expectancy great 3 month 2.1.1.4 Histologically confirm cancer 2.1.1.5 Extracranial metastatic cancer locally advance cancer palliative radiotherapeutic management would appropriate ( two site treat trial ) 2.1.1.6 Patients must measurable evaluable disease site ( ) require radiation 2.1.1.7 Adequate marrow organ function define absolute neutrophil count ( ANC ) &gt; 1.5 time 10 ( 9 ) /L , platelet count &gt; 100 time 10 ( 9 ) , hemoglobin &gt; 9 g/L . creatinine clearance great equal 60 mL/min/1.73 ( 2 ) patient creatinine level institutional normal serum bilirubin &lt; 1.5 time upper limit reference range ( ULRR ) , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , alkaline phosphatase ( ALP ) &lt; 2.5 time ULRR ( &lt; 5 time ULRR presence liver metastasis ) 2.1.1.8 Female patient child bear potential must either surgically sterile prevent pregnancy , least 1year postmenopausal , menses 12 month , agree use reliable method contraception ( oral contraceptive , barrier method , approve contraceptive implant , longterm injectable contraception , copper band intrauterine device , tubal ligation abstinence ) time screen 4 week discontinue study treatment . It know whether ECI301 capacity induce hepatic enzyme hormonal contraceptive combine barrier method contraception . 2.1.1.9 Male patient must agree use barrier contraception ( i.e . condom ) refrain donate sperm start dose 16 week discontinue study treatment . If male patient wish father child advise arrange freeze sperm prior start study treatment . EXCLUSION CRITERIA : 2.1.2.1 Pregnant lactating female 2.1.2.2 Contraindications radiotherapy ( i.e . prior radiotherapy intend treatment site ) 2.1.2.3 Untreated previously treat progressive intracranial metastasis ( Patients previously treat intracranial metastasis clinical evidence progression least 4 week therapy intracranial metastasis ) 2.1.2.4 Need emergent radiotherapy ( define need radiotherapy within 24 hour consultation judgment treat radiation oncologist ) 2.1.2.5 Active treatment immunosuppressive therapy subject take systemic corticosteroid therapy reason include replacement therapy hypoadrenalism 2.1.2.6 Chemotherapy , radiation therapy , Tamoxifen investigational therapy 4 week prior initiation protocol therapy 2.1.2.7 History rheumatoid arthritis , systemic lupus erythematosus , Sj ( SqrRoot ) ( Delta ) grens disease , sarcoidosis , vasculitis , polymyositis , temporal arteritis autoimmune disease 2.1.2.8 History organ transplant 2.1.2.9 HIV , Hepatitis B , Hepatitis C positivity 2.1.2.10 Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement 2.1.2.11 Use exclude immune modulating medication within 4 week prior protocol therapy , requirement concurrent use .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 24, 2013</verification_date>
	<keyword>Metastasis</keyword>
	<keyword>Cancer</keyword>
	<keyword>Radiation Therapy</keyword>
	<keyword>Locally Advanced</keyword>
	<keyword>Palliation</keyword>
	<keyword>Metastatic Cancer</keyword>
</DOC>